NO20071375L - Bilags tablett. - Google Patents

Bilags tablett.

Info

Publication number
NO20071375L
NO20071375L NO20071375A NO20071375A NO20071375L NO 20071375 L NO20071375 L NO 20071375L NO 20071375 A NO20071375 A NO 20071375A NO 20071375 A NO20071375 A NO 20071375A NO 20071375 L NO20071375 L NO 20071375L
Authority
NO
Norway
Prior art keywords
tablet
appendix
layer
immediate release
formulated
Prior art date
Application number
NO20071375A
Other languages
English (en)
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36145644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071375(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20071375L publication Critical patent/NO20071375L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en tolagstablett omfattende et første lag formulert for umiddelbar frigjøring av angiotensin II reseptorantagonisten telmisartan fra en oppløsende tablettmatriks, og et andre lag formulert for umiddelbar frigjøring av HMG-CoA reduktaseinhibitoren simvastatin fra en desintegrerende eller eroderende tablettmatriks.
NO20071375A 2004-10-12 2007-03-14 Bilags tablett. NO20071375L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04024239 2004-10-12
PCT/EP2005/010812 WO2006040085A2 (en) 2004-10-12 2005-10-07 Bilayer tablet

Publications (1)

Publication Number Publication Date
NO20071375L true NO20071375L (no) 2007-05-10

Family

ID=36145644

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071375A NO20071375L (no) 2004-10-12 2007-03-14 Bilags tablett.

Country Status (17)

Country Link
US (1) US20060078615A1 (no)
EP (1) EP1802283A2 (no)
JP (1) JP2008515838A (no)
KR (1) KR20070064366A (no)
CN (1) CN101052380A (no)
AR (1) AR052775A1 (no)
AU (1) AU2005293773A1 (no)
BR (1) BRPI0516073A (no)
CA (1) CA2578447A1 (no)
EA (1) EA200700765A1 (no)
EC (1) ECSP077381A (no)
IL (1) IL182455A0 (no)
NO (1) NO20071375L (no)
TW (1) TW200628174A (no)
UY (1) UY29160A1 (no)
WO (1) WO2006040085A2 (no)
ZA (1) ZA200701098B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CN101219120B (zh) * 2007-12-27 2011-02-23 江苏万邦生化医药股份有限公司 替米沙坦分散片及其制备方法
WO2009120052A1 (es) * 2008-03-24 2009-10-01 Laboratorios Pisa, S.A. De C.V. Composición farmacéutica con efecto sinérgico para el tratamiento de hipertensión arterial y dislipidemia
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
WO2010021473A2 (ko) * 2008-08-19 2010-02-25 한올제약주식회사 약제학적 제제
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
JP5776776B2 (ja) * 2011-08-05 2015-09-09 富士通株式会社 データ処理システム、およびデータ処理方法
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
ES3009527T3 (en) * 2014-07-25 2025-03-27 Laurent Pharmaceuticals Solid oral formulation of fenretinide
CN104739833A (zh) * 2015-02-16 2015-07-01 江苏欧信医药化工有限公司 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
CA2987071A1 (en) * 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
KR101883091B1 (ko) * 2017-01-18 2018-07-27 아주대학교산학협력단 안지오텐신 수용체 차단제 및 HMG-CoA 환원효소 억제제를 유효성분으로 함유하는 이층정 복합제제 및 이의 제조방법
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
HRP20040649B1 (en) * 2002-01-16 2012-12-31 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20050004193A1 (en) * 2003-01-16 2005-01-06 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
AU2005293773A1 (en) 2006-04-20
WO2006040085A2 (en) 2006-04-20
IL182455A0 (en) 2007-07-24
EA200700765A1 (ru) 2007-10-26
ZA200701098B (en) 2009-06-24
TW200628174A (en) 2006-08-16
US20060078615A1 (en) 2006-04-13
WO2006040085A3 (en) 2007-03-15
JP2008515838A (ja) 2008-05-15
KR20070064366A (ko) 2007-06-20
BRPI0516073A (pt) 2008-08-19
ECSP077381A (es) 2007-05-30
CN101052380A (zh) 2007-10-10
AR052775A1 (es) 2007-04-04
UY29160A1 (es) 2006-05-31
EP1802283A2 (en) 2007-07-04
CA2578447A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
NO20063997L (no) Tablett med flere lag
NO20071514L (no) Tolags tablett inneholdende Telmisartan og Amlodipin
ECSP077381A (es) Comprimido bicapa
CY1114929T1 (el) Φαρμακευτικο δισκιο δυο-στιβαδων το οποιο περιλαμβανει τελμισαρτανη και ενα διουρητικο
NO20073396L (no) Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor
IS8332A (is) Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma
ECSP105695A (es) Proceso para la fabricacion de valsartan
CL2011001091A1 (es) Forma de dosificacion farmaceutica oral solida que comprende en su nucleo nifedipino o nisoldipino y en un revestimiento de manto alrededor del nucleo al menos un antagonista de angiotensina ii y/o al menos un diuretico; procedimiento para su preparacion, util para tratar hipertension.
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
EP1903144A4 (en) FADEN AND METHOD OF MANUFACTURING THEREOF, FAKE-PROOF FORM AND PRINTING MATERIAL THEREOF, AND THE FAKE-PRODUCING APPROACH THEREOF
EP2086519A4 (en) COMPLEX COMPOSITION WITH CONTROLLED RELEASE WITH ANGIOTENSIN II RECEPTOR BLOCKERS AND HMG COA REDUCTASE INHIBITORS
DK2027096T3 (da) Substituerede arylimidazoloner og -triazoloner som inhibitorer for vasopressinreceptorerne
ECSP10010160A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
NO20040211L (no) Kombinasjon av en aldosteronreseptor for antagonist og en HMB COA-reduktaseinhibitor
AR061047A1 (es) Comprimido bicapa para la prevencion de los accidentes cardiovasculares, su uso, y metodo para la prevencion de accidentes cardiovasculares
PT3000810T (pt) Derivados de benzimidazole alquilado n3 como inibidores de mek
EA201001312A1 (ru) Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик
CL2007003613A1 (es) Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension.
ATE520129T1 (de) Strahlenschutzkammer
RU2016126852A (ru) Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы
MX2007011607A (es) Metodo para reducir el riesgo de eventos cardiovasculares adversos (cv) asociados con la administracion de agentes farmaceuticos que favorecen los eventos cv.
UA86417C2 (ru) СОЕДИНЕНИЕ ИНГИБИТОРА Іf-КАНАЛОВ СИНУСНОГО УЗЛА И ИНГИБИТОРА АНГИОТЕНЗИНПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ
NO20072615L (no) Biomarkor for hjertesvikt
WO2009061786A3 (en) Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2007017469A3 (en) Process for preparing an angiotensin ii receptor antagonist

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application